Can I Take St. John's Wort with Enclomiphene Citrate?

Two substances that should not be confused

Enclomiphene citrate is the trans-isomer of clomiphene citrate (brand name Clomid contains both the trans- and cis-isomers). Enclomiphene alone was studied under the investigational name Androxal for male secondary hypogonadism, but it is not FDA-approved and is currently prescribed off-label, typically at 12.5-25 mg daily. It works by blocking estrogen receptors in the hypothalamus, which raises LH and FSH and secondarily raises testosterone, without the direct suppression of the hypothalamic-pituitary-gonadal axis seen with exogenous testosterone.

St. John's Wort (Hypericum perforatum) is an unrelated herbal supplement sold over the counter for mild depression, anxiety, and sleep. It is not a hormone or receptor ligand at supplement doses. Its relevance here is entirely pharmacokinetic: it changes how the body clears other drugs.

These are not sibling compounds and do not interact through a shared receptor. The concern is that one changes the metabolism of the other.

The direct answer, with its boundary

Enclomiphene citrate, the trans-isomer of clomiphene citrate, is not FDA-approved and is prescribed off-label for male secondary hypogonadism. St. John's Wort is an FDA-flagged inducer of CYP3A4 and P-glycoprotein through its hyperforin constituent, an effect established using other CYP3A4 substrate drugs, not enclomiphene itself. No published pharmacokinetic study has measured enclomiphene levels with concurrent St. John's Wort use, so the recommendation to avoid the combination is a mechanistic extrapolation from drug-class behavior rather than a directly measured drug interaction.

What is actually established about enclomiphene's metabolism

Clomiphene isomers undergo hepatic oxidative metabolism. A pharmacokinetic study examined CYP2D6-mediated oxidative metabolism of clomiphene and its enantiomers, and found a role for CYP2D6 in processing these isomers. This is worth stating plainly because it complicates a simple CYP3A4 story: the best available enclomiphene-specific pharmacokinetic literature we have access to points to CYP2D6 involvement, not a clearly established primary role for CYP3A4. Broader pharmacokinetic characterization of enclomiphene, including its terminal half-life, has been reported in other literature, though the specifics require direct verification, but a full, publicly reconciled account of which CYP enzymes dominate enclomiphene clearance, and by how much, is not something this reference set can confirm with precision. That gap should be verified directly with a pharmacist or the prescribing clinician before treating any specific percentage as reliable.

What is not in dispute is that enclomiphene's therapeutic effect depends on adequate hypothalamic drug exposure. If any factor, metabolic or otherwise, meaningfully lowers plasma concentration, the estrogen-receptor blockade at the hypothalamus weakens, and the downstream LH/FSH/testosterone rise would be expected to blunt.

What is established about St. John's Wort's effect on other drugs

This side of the interaction has strong direct evidence, just not for enclomiphene specifically.

• Regulatory safety communications have described St. John's Wort as capable of reducing blood levels of a range of drugs, including indinavir, cyclosporine, oral contraceptives, warfarin, and digoxin, through induction of drug-metabolizing enzymes.
• Hyperforin, a constituent of St. John's Wort, activates the pregnane X receptor, which up-regulates transcription of CYP3A4 and related enzymes; this mechanism was characterized in laboratory and human studies by Moore et al. [4].
• Dresser et al. documented coordinate induction of CYP3A4 activity and the P-glycoprotein transporter (MDR1) in healthy subjects taking St. John's Wort, supporting a dual mechanism: faster hepatic clearance plus reduced intestinal absorption for susceptible drugs [6].
• A broader review by Borrelli and Izzo catalogs herb-drug interactions with St. John's Wort across multiple CYP3A4-dependent medications, generally describing meaningful reductions in blood levels for affected drugs, though the exact magnitude varies by drug, dose, and St. John's Wort formulation [3].
• A documented case report describes acute heart transplant rejection attributed to falling cyclosporine levels during concurrent St. John's Wort use, illustrating that this is not a theoretical concern for CYP3A4-cleared drugs generally [8].

Onset of induction is generally described as beginning within the first week of daily use and reaching a fuller effect within about two weeks; induction is also reported to persist for a period after St. John's Wort is stopped, commonly cited as roughly two weeks, before enzyme activity returns toward baseline [3]. These figures come from studies of other CYP3A4 substrates, not enclomiphene.

Should you combine them: the honest reasoning chain

The case for caution is a chain of plausible, individually-supported steps rather than one direct finding:

1. Clomiphene isomers are metabolized through CYP450 pathways, with documented CYP2D6 involvement and a possible but not fully confirmed CYP3A4 contribution.
2. St. John's Wort reliably induces CYP3A4 and P-glycoprotein for many other drugs [3][4][6].
3. If enclomiphene clearance is meaningfully CYP3A4- or P-gp-dependent, St. John's Wort would be expected to lower enclomiphene plasma levels.
4. Lower plasma levels would be expected to reduce hypothalamic estrogen-receptor blockade and blunt the LH/FSH/testosterone response.

Each link is plausible. None of them has been tested end to end for this specific drug pair. That is the honest evidence boundary, and it is the reason this page recommends caution rather than claiming a proven interaction.

Evidence-status interaction assessment

What happens clinically if enclomiphene is undertreated

Secondary hypogonadism that goes inadequately treated is not a cosmetic issue. A systematic review and meta-analysis has reported associations between lower testosterone and higher rates of metabolic syndrome and related cardiovascular risk markers. That review describes population-level associations, not a guarantee for any individual, and it does not establish what happens specifically when enclomiphene is undertreated due to a supplement interaction rather than untreated hypogonadism generally. The practical concern is narrower and more immediate: a patient who silently gets less drug than intended may be labeled a "treatment failure" and have their dose escalated or their diagnosis reconsidered, when the actual issue is a supplement interaction that a medication history would have caught.

A monitoring approach if both are already in use

If someone is taking both St. John's Wort and enclomiphene, or considering starting one while on the other, a reasonable monitoring conversation with a prescriber includes:

• Baseline total testosterone, free testosterone, LH, FSH, and estradiol before combining or before making any changes
• A recheck of total testosterone and LH around 4 weeks into treatment
• Interpreting a flat LH response despite adequate enclomiphene dosing as a signal to ask specifically about St. John's Wort or other supplement use, alongside other explanations (nonadherence, absorption issues, primary testicular dysfunction)
• If St. John's Wort is stopped, waiting roughly two weeks before drawing conclusions about enclomiphene efficacy, since induction does not resolve immediately [3]

Do not increase enclomiphene dose on your own to compensate for a suspected interaction. Supraphysiologic dosing of estrogen-receptor modulators carries its own risks, including mood changes and visual disturbances, and self-adjustment removes the ability to tell whether an interaction or something else is the actual cause.

If you take St. John's Wort for depression or anxiety

A Cochrane review by Linde, Berner, and Kriston, covering 29 trials, found St. John's Wort more effective than placebo and broadly comparable to standard antidepressants for mild-to-moderate depression [9]. That is a real and relevant benefit for some patients, which is why this page does not simply tell every reader to discard the supplement. It does mean the decision is a tradeoff, not a one-sided safety call: standard SSRIs and SNRIs do not induce CYP3A4 at therapeutic doses and would not carry this particular interaction risk, but they carry their own side-effect profile and are not interchangeable with St. John's Wort for every patient. That tradeoff is worth discussing directly with the prescriber managing the hypogonadism treatment, ideally alongside whoever is treating the mood condition.

Other CYP3A4-dependent drugs affected by St. John's Wort

Placing enclomiphene alongside other CYP3A4 substrates shows why the caution is proportionate even without direct data:

• Cyclosporine: a documented case of acute transplant rejection has been linked to falling cyclosporine levels during St. John's Wort use [8]
• Oral contraceptives: breakthrough bleeding and reports of contraceptive failure are described in the interaction literature [3]
• Indinavir and other antiretrovirals: this interaction is a commonly cited concern with CYP3A4-inducing supplements
• Warfarin: INR instability from accelerated metabolism is a recognized concern, involving CYP2C9 as well as CYP3A4 [3]

Enclomiphene's consequence of failure is different from cyclosporine's; a blunted testosterone response is not an acute emergency. The mechanism category, however, is the same well-documented enzyme system.

Lower-risk supplement alternatives to discuss with a prescriber

Not every supplement carries this induction risk. A few commonly used for men's hormonal health have little or no known CYP3A4 induction:

• Vitamin D3: no meaningful CYP3A4 induction; a supplementation study reported testosterone changes in vitamin D-deficient men, though this is a specific population and result, not a general testosterone-boosting claim [10]
• Zinc: no known CYP3A4 interaction
• Magnesium glycinate: no known CYP interaction
• Ashwagandha (Withania somnifera): limited CYP induction data available; a small randomized crossover trial in aging, overweight men reported an increase in testosterone versus placebo, but the sample size was small and this should be discussed with a prescriber before combining, not assumed to be interaction-free in all contexts [11]

None of these substitute for St. John's Wort's antidepressant effect, and none of this is a recommendation to self-treat depression or hypogonadism with supplements instead of prescribed therapy.

What to do if you are already taking both

1. Tell your prescriber about the St. John's Wort use at your next visit, or sooner if labs already show a poor testosterone response.
2. Do not stop either medication abruptly without guidance.
3. If the plan is to stop St. John's Wort, allow roughly two weeks before re-evaluating enclomiphene efficacy with labs.
4. Recheck total testosterone and LH after that washout period; some patients will see improvement without any dose change.
5. If St. John's Wort is being used for a mood condition, discuss alternatives with the prescriber managing that condition rather than stopping it unilaterally.

When this becomes an urgent issue rather than a monitoring issue

This interaction is about reduced efficacy, not acute toxicity, and it does not on its own require emergency care. Seek prompt medical attention if you experience symptoms unrelated to this interaction pattern, such as chest pain, sudden vision changes, signs of a blood clot, or severe mood changes including suicidal thoughts, since these require direct evaluation regardless of supplement use.

Summary of what is known and unknown